[1] [3] According to the UK SmPC, dosing starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg increments every 4 weeks until the target dose (5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg) is reached, based on individual response and tolerability
Conversely, increased CAT was observed in the hypothalamus and posterior cortex of VPA-exposed animals
[26] [27] Non-fasting samples are acceptable for routine monitoring
Our experts monitor your progress, ensuring optimal health throughout your journey
Nausea, constipation, and reduced appetite are expected
Intranasal insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and alzheimers disease